Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
20 authors.
Mateus Sá Magalhães SerafimCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-7505-8659
Thales KronenbergerInstitut für Medizinische Mikrobiologie und Hygiene and DZIF (Center for Infection Research) Partner-site Tübingen, Tübingen, Germany.ORCID 0000-0001-6933-7590
Karol R FranciscoCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-9742-8801
Erik Vinicius de Sousa ReisDepartment of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Minas Gerais, Brazil.ORCID 0000-0001-5442-6240
Ellen Gonçalves de OliveiraCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Fernanda Kelly Marcelino E OliveiraDepartment of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Minas Gerais, Brazil.
Isadora Serraglio FortesCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-3260-4242
Thaís Helena Maciel FernandesCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-5910-0792
Elany Barbosa da SilvaCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-1926-3500
Pavla FajtovaCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-4029-0706
Danielle E SkinnerCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Rafay O SyedCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
Jair Lage de Siqueira-NetoCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-9574-8174
Antti PosoSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0003-4196-4204
Bruno Eduardo Fernandes MotaDepartament of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Minas Gerais, Brazil.ORCID 0000-0003-0348-4875
Jordana Grazziela Alves Coelho-Dos-ReisDepartment of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Minas Gerais, Brazil.ORCID 0000-0002-2360-1875
Jônatas Santos AbrahãoDepartment of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Minas Gerais, Brazil.ORCID 0000-0001-9420-1791
Vinícius Gonçalves MaltarolloDepartment of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Minas Gerais, Brazil.ORCID 0000-0001-9675-5907
Anthony J O'DonoghueCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-5695-0409
Conor R CaffreyCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-3048-8572
Funding
RESEARCH IN INFECTIOUS DISEASEST32AI007036 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIZET, VICTOR · 1985 to 2025
$9.2M
NIAID NIH HHS T32 AI007036
6 · The paper itself
Abstract
The constant emergence of SARS-CoV-2 resistance drives the search for new antivirals. We screened the SARS-CoV-2 cysteine proteases, the main protease (M
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Discovery of benzyl carbamate inhibitors of coronavirus M · full record | OpenQuestion